{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"261"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"10"}],"units":"Participants"}],"title":"Baseline nivolumab ADA-positive"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"235"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"261"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"10"}],"units":"Participants"}],"title":"Baseline nivolumab ADA-negative"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"57"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"249"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"9"}],"units":"Participants"}],"title":"Nivolumab ADA-positive"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"192"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"249"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"9"}],"units":"Participants"}],"title":"Nivolumab ADA-negative"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"261"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"10"}],"units":"Participants"}],"description":"Anti-drug antibodies (ADA) to nivolumab in serum were measured by a validated electrochemiluminescence assay.\n\nBaseline ADA Positive is defined as participants who had a baseline ADA sample which tested as positive for an anti-drug antibody against cabiralizumab; Post baseline ADA Positive is defined as participants that either had 1) an ADA detected (positive seroconversion) sample in a participant for whom ADA was not detected at baseline, or (2) an ADA detected sample with ADA titer at least 4-fold or greater than the baseline positive titer; Post baseline ADA Negative: Participants who never reported an ADA-positive sample after the initiation of treatment.","groups":[{"description":"Participants received 1 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG000","title":"Cabiralizumab 1mg/kg + Nivolumab 3 mg/kg Q2W"},{"description":"Participants received 2 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG001","title":"Cabiralizumab 2 mg/kg + Nivolumab 3 mg/kg Q2W"},{"description":"Participants received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG002","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W"},{"description":"Participants received 6 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG003","title":"Cabiralizumab 6 mg/kg + Nivolumab 3 mg/kg Q2W"},{"description":"Participants received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV every 3 weeks (Q3W) until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG004","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q3W"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants who received at least 1 dose of nivolumab and had available ADA data at baseline and post-baseline.","reportingStatus":"POSTED","timeFrame":"Blood samples were collected before the infusion on Cycles 1 (Baseline), 2, 3, 4, 5, 9, 13, and 21, and at 28 days and 100 days after the end of treatment","title":"Immunogenicity of Nivolumab: Number of Participants With Anti-Nivolumab Antibodies (Phase 1a and 1b)","type":"SECONDARY","unitOfMeasure":"Participants"}